Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (6621)	5/10/1999 8:14:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 7041

Linda....check this out..... #reply-9450420 If this hold true then SGP is cutting it's loses on ZONA ....IMO

To: Linda Kaplan who wrote (6621)	5/11/1999 12:38:00 AM
From: BDR	Read Replies (1) \| Respond to of 7041

Maybe this is why SGP didn't drop today. They got approval to market a real drug. *********** Schering-Plough (SGP) received approval to market Rebetol (Rebetron), its drug for Hepatitis C, in Europe. Given that Europe has a slightly larger Hepatitis C market (5 million) versus the US (4 million), analysts think that this product could have peak international sales of at least $400-$500 million. However, it was also announced today, that SGP received a non-approvable letter from the FDA for Vasomax, its drug for male erectile dysfunction. The company will do more studies on this drug and try to resubmit it later. Given the low expectations for this drug, investors largely ignore the impact of this ruling. edit-sorry, I left out the attribution: labpuppy.com